| 274901-16-5 Basic information More.. |
Product Name: | Vildagliptin | Synonyms: | Vidagliptin (see vildagliptin);Vildagliptin;1-[2-(3-HydroxyadaMant-1-ylaMino)acetyl]pyrrolidine-2(S)-carbonitrile;(S)-1-[2-((5S,7S)-3-hydroxy-adaMantan-1-ylaMino)-acetyl]-pyrrolidine-2-carbonitrile;NVP-LAF 237;ZoMelis;Vildagliptin API;Vildagliptin (NVP-LAF 237) | CAS: | 274901-16-5 | MF: | C17H25N3O2 | MW: | 303.4 | EINECS: | 630-410-0 | Mol File: | 274901-16-5.mol | |
Use
Vildagliptin, a DPP-4 inhibitor, was launched for the oral treatment of type 2 diabetes. Vildagliptin is the second DPP-4 inhibitor to reach the market behind sitagliptin, which was introduced in 2006. DPP-4 inhibitors act by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase the synthesis and release of insulin from pancreatic βcells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic α cells, which leads to reduced hepatic glucose production. However, although GLP-1 and GIP effectively lower blood glucose, they are short-lived as a result of rapid inactivation by the ubiquitous serine protease DPP-4. By inhibiting DPP-4, vildagliptin increases the concentration and duration of active incretin levels, which in turn results in increased insulin release and decreased glucagon levels in a glucose-dependent manner. Both vildagliptin and sitagliptin are potent, competitive, reversible inhibitors of DPP- 4 (IC50=3.5 and 18 nM, respectively), and they both show slow, tight-binding inhibition kinetics.
- Vildagliptin
-
- US $0.00-0.00 / Kg/Bag
- 2024-03-26
- CAS:274901-16-5
- Min. Order: 1Kg/Bag
- Purity: 99% up, High Density
- Supply Ability: 20 tons
- Vildagliptin
-
- US $35.00-25.00 / kg
- 2024-03-15
- CAS:274901-16-5
- Min. Order: 1kg
- Purity: 99.8%
- Supply Ability: 200tons/year
|
274901-16-5
Recommend Suppliers |
|